Invesaro

Stocks SPRY Earnings

Earnings

ARS Pharmaceuticals, Inc. (SPRY) earnings

Quarterly results of ARS Pharmaceuticals, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when SPRY files with the SEC.

Next earnings date

ARS Pharmaceuticals, Inc. is expected to report around March 8, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Latest quarter: Q3 FY2026

In Q3 FY2026 (ended September 30, 2026) ARS Pharmaceuticals, Inc. reported revenue of $37.7M (+16% on the same quarter a year earlier) and a net loss of $35.6M.

Diluted earnings per share were -$0.36.

Filed with the SEC on November 5, 2026.

Revenue by quarter
Q4 24: $86.6M $86.6M Q4 24Q1 25: $8M $8M Q1 25Q2 25: $15.7M $15.7M Q2 25Q3 25: $32.5M $32.5M Q3 25Q4 25: $28.1M $28.1M Q4 25Q1 26: $22.7M $22.7M Q1 26Q2 26: $33.7M $33.7M Q2 26Q3 26: $37.7M $37.7M Q3 26
Net income by quarter
Q4 24: $49.9M $49.9M Q4 24Q1 25: -$33.9M -$33.9M Q1 25Q2 25: -$44.9M -$44.9M Q2 25Q3 25: -$51.2M -$51.2M Q3 25Q4 25: -$41.3M -$41.3M Q4 25Q1 26: -$60.6M -$60.6M Q1 26Q2 26: -$62.3M -$62.3M Q2 26Q3 26: -$35.6M -$35.6M Q3 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q3 FY2026September 30, 2026$37.7M+16%-$35.6M-$0.36
Q2 FY2026June 30, 2026$33.7M+114.2%-$62.3M-$0.63
Q1 FY2026March 31, 2026$22.7M+184.5%-$60.6M-$0.61
Q4 FY2025December 31, 2025$28.1M-67.6%-$41.3M-
Q3 FY2025September 30, 2025$32.5M--$51.2M-$0.52
Q2 FY2025June 30, 2025$15.7M--$44.9M-$0.46
Q1 FY2025March 31, 2025$8M--$33.9M-$0.35
Q4 FY2024December 31, 2024$86.6M-$49.9M-

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

When is ARS Pharmaceuticals, Inc.'s next earnings date?

ARS Pharmaceuticals, Inc. is expected to report around March 8, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

What were ARS Pharmaceuticals, Inc.'s latest quarterly results?

For Q3 FY2026, which ended September 30, 2026, ARS Pharmaceuticals, Inc. reported revenue of $37.7M and a net loss of $35.6M. The figures come from its filing with the SEC.

Is ARS Pharmaceuticals, Inc.'s revenue growing?

Revenue in Q3 FY2026 was $37.7M, up 16% from $32.5M in the same quarter a year earlier.

Get an email when SPRY reports

Follow SPRY and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when SPRY files with the SEC.

Source: quarterly figures ARS Pharmaceuticals, Inc. tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about ARS Pharmaceuticals, Inc.